FDA Grants Orphan Drug Status to Seres for Pediatric Ulcerative Colitis Therapy
News
Seres Therapeutics has secured an orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for SER-287, its therapy to treat ulcerative colitis in children. ODD offers companies incentives ... Read more